Weekly Low-Dose Docetaxel-Based Chemoradiotherapy for Locally Advanced Oropharyngeal or Hypopharyngeal Carcinoma: A Retrospective, Single-Institution Study
- Department of Radiology, Keio University, School of Medicine, Tokyo (Japan)
- Department of Radiology, Ofuna Chuo Hospital, Kanagawa (Japan)
- Department of Otolaryngology, Keio University, School of Medicine, Tokyo (Japan)
- Department of Otolaryngology-Head and Neck Surgery, National Defense Medical College, Saitama (Japan)
Purpose: To retrospectively assess the efficacy, toxicity, and prognostic factors of weekly low-dose docetaxel-based chemoradiotherapy for Stage III/IV oropharyngeal or hypopharyngeal carcinoma. Methods and Materials: Between 2001 and 2005, 72 consecutive patients with locally advanced oropharyngeal or hypopharyngeal carcinoma were treated with concurrent chemoradiotherapy (CCR; radiation at 60 Gy plus weekly docetaxel [10 mg/m{sup 2}]). Thirty of these patients also received neoadjuvant chemotherapy (NAC; docetaxel, cisplatin, and 5-fluorouracil) before concurrent chemoradiotherapy. Survival was calculated according to the Kaplan-Meier method. The prognostic factors were evaluated by univariate and multivariate analyses. Results: The median follow-up was 33 months, with overall survival, disease-free survival, and locoregional control rates at 3 years of 59%, 45%, and 52%, respectively. Thirty-six patients (50%) experienced more than one Grade 3 to 4 acute toxicity. Grade 3 mucositis occurred in 32 patients (44%), Grade 4 laryngeal edema in 1 (1%). Grade >=3 severe hematologic toxicity was observed in only 2 patients (3%). Grade 3 dysphagia occurred as a late complication in 2 patients (3%). Multivariate analyses identified age, T stage, hemoglobin level, and completion of weekly docetaxel, but not NAC, as significant factors determining disease-free survival. Conclusions: Docetaxel is an active agent used in both concurrent and sequential chemoradiotherapy regimens. Mucositis was the major acute toxicity, but this was well tolerated in most subjects. Anemia was the most significant prognostic factor determining survival. Further studies are warranted to investigate the optimal protocol for integrating docetaxel into first-line chemoradiotherapy regimens, as well as the potential additive impact of NAC.
- OSTI ID:
- 21372055
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 76, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2009.01.056; PII: S0360-3016(09)00219-3; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Radiotherapy and Concomitant Intra-Arterial Docetaxel Combined With Systemic 5-Fluorouracil and Cisplatin for Oropharyngeal Cancer: A Preliminary Report-Improvement of Locoregional Control of Oropharyngeal Cancer
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck
Related Subjects
ANEMIAS
ANTINEOPLASTIC DRUGS
CARCINOMAS
CHEMOTHERAPY
COMBINED THERAPY
MULTIVARIATE ANALYSIS
PHARYNX
RADIOTHERAPY
SURVIVAL CURVES
TOXICITY
URACILS
AZINES
BODY
DIGESTIVE SYSTEM
DISEASES
DRUGS
HEMIC DISEASES
HETEROCYCLIC COMPOUNDS
HYDROXY COMPOUNDS
MATHEMATICS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PYRIMIDINES
RADIOLOGY
RESPIRATORY SYSTEM
STATISTICS
SYMPTOMS
THERAPY